Diabetic retinopathy: A comprehensive review

Indian Journal of Medical Sciences

Volumn 62, Issue 12, 2008, Pages 500-519

  Shah, Chirag ^a  

^a Accelaire Consulting and Research Pvt Ltd   (India)

Author keywords

Diabetic retinopathy; Management; Pathophysiology

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ATORVASTATIN; BEVACIZUMAB; CANDESARTAN; CELECOXIB; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FLUOCINOLONE ACETONIDE; GLUCOSE; HORMONE INHIBITOR; INSULIN; LIPID; LISINOPRIL; LOSARTAN; MIDOSTAURIN; OCTREOTIDE; PEGAPTANIB; PLACEBO; POLYOL; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; SIMVASTATIN; SOMATOSTATIN; STEROID; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

BLINDNESS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; DYSLIPIDEMIA; EYE EXAMINATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HORMONE INHIBITION; HUMAN; HYPERTENSION; INFLUENZA; LASER COAGULATION; LIPID BLOOD LEVEL; METABOLIC REGULATION; NONHUMAN; OXIDATION; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PROLIFERATIVE RETINOPATHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA MACULOPATHY; REVIEW; RISK FACTOR; VISUAL IMPAIRMENT; VITRECTOMY;

BLINDNESS; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; HYPERTENSION; INDIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 62249104346     PISSN: 00195359     EISSN: 19983654     Source Type: Journal    
DOI: 10.4103/0019-5359.48562     Document Type: Review

References (94)

1. World Health Organization (www.who.int). Geneva. Diabetes fact sheet number 312. [updated on 2008 Nov]; [cited on 2008 Nov 25]. Available from: http://www.who.int/mediacentre/ factsheets/fs312/en.
2. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, et al. Diabetic retinopathy. Diabetes Care 1998;21:143-56.
3. Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complications of diabetes. Vitam Horm 2000;60:149-93.
4. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993;265:783-93.
5. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89:11059-63.
6. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, et al. Characterization of vascular endothelial growth factor.s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-26.
7. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabete Metab Rev 1997;13:37-50.
8. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101:527-37.
9. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001;27:535-42.
10. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991;88:11555-8.
11. Frank RN, Keirn RJ, Kennedy RA, Frank KW. Galactose induced retinal basement membrane thickening: Prevention by sorbinil. Invest Ophthalmol Vis Sci 1983;24:1519-24.
12. Engerman RL, Kern TS. Experimental galactosemia produces diabetic-like retinopathy. Diabetes 1984;33:97-100.
13. Gabbay KH. Hyperglycemia, polyol metabolism and complications of diabetes mellitus. Annu Rev Med 1975;26:521-36.
14. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.
15. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-90.
16. Kunisaki M, Bursell SE, Clermont AC, Ishii H, Ballas LM, Jirousek MR, et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 1995;269:239-46.
17. Bursell SE, King GL. Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diabetes Res Clin Pract 1999;45:169-82.
18. Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999;22:1245-51.
19. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
20. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61.
21. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoformselective inhbitor. Diabetes 1997;46:1473-80.
22. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin GF, Kohner EM. Long term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987;30:199-207.
23. Watkins PJ. ABC of diabetes-Retinopathy. BMJ 2003:326:924-6.
24. Hudson C. A clinical perspective of diabetic retinopathy. Geriatr Aging 2008;11:333-41.
25. Yam J, Kwok A. Update on the treatment of diabetic retinopathy. Hong Kong Med J 2007;13:46-60.
26. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-71.
27. Klein R, Palta M, Allen C, Shen G, Han DP, D.Alessio DJ. Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. Arch Ophthalmol 1997;115:351-6.
28. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-61.
29. Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
30. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83.
31. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9.
32. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
34. Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulindependent diabetes mellitus: A meta-analysis. Diabetes Med 1997;14:919-28.
35. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:15-35.
36. Suzuma I, Hata Y, Clermont A, Pokras F, Rook SL, Suzuma K, et al. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: Potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 2001;50:444-54.
37. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631-40.
38. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23:54-64.
39. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
40. Danser AH, Derkx FH, Admiraal PJ, Deinum J, Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994;35:1008-18.
41. Wagner J, Danser AH, Derkx FH, Jong TV, Paul M, Mullins JJ, et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: Evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996;80:159-63.
42. Engler CB, Parving HH, Mathiesen ER, Larsen M, Andersen H. Blood-retina barrier permeability in diabetes during acute ACE inhibition. Acta Ophthalmol 1991;69:581-5.
43. Hogeboom van Buggenum IM, Polak BC, Thoen JW, Knoppert WA, Hinsbergh VW, Tangelder GJ. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002;45:203-9.
44. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circulation Res 1998;82:619-28.
45. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002;86:311-5.
46. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000;36:1099-104.
47. Nagisa Y, Shintani A, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 2001;44:883-8.
48. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
49. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials. Lancet 2008;372:1394-402.
50. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet 2008;372:1385-93.
51. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84.
52. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, et al. Diabetic Retinopathy and Serum Lipoprotein Subclasses in the DCCT/ EDIC Cohort. Investig Ophthalmol Visual Sci 2004;45:910-8.
53. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969;18:285-91.
54. Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 1974;94:554-62.
55. Keech AC, Mitchell P, Summanen PA, O.Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007;370:1687-97.
56. Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, Ha J, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007;84:886-93.
57. Dowler JG. Laser management of diabetic retinopathy. J R Soc Med 2003;96:277-9.
58. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. JAMA 2007;298:902-16.
59. Photocoagulation treatment of proliferative diabetic retinopathy: The second report of diabetic retinopathy study findings. Ophthalmology 1978;85:82-106.
60. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings: DRS Report Number 8. Ophthalmology 1981;88:583-600.
61. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7. Ophthalmology 1991;98:741-56.
62. Diabetic Retinopathy Vitrectomy Study Research group. Early vitrectomy for severe vitreous haemorrhage in eyes with useful vision: Clinical applications of results of a randomized trial: Diabetic Retinopathy Vitrectomy Study report 4. Ophthalmology 1988;95:1321-34.
63. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
64. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987;94:761-74.
65. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-8.
66. Pearson P, Levy B, Comstock T. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial: Poster presented at the Association for Research in Vision and Ophthalmology, April 30-May 4, 2006, Fort Lauderdale, Fla., Abstract 5442.
67. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA; Posurdex Study Group. An intravitreous dexamethasone bioerodible drug delivery system for the treatment of persistent diabetic macular edema. Invest Ophthalmol Vis Sci 2003;44:E-abstract 4289. Available from: http:// abstracts.iovs.org.
68. Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D.Amico DJ, et al. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-57.
69. Adamis AP, Altaweel M, Bressler NM, Cunningham ET, Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-8.
70. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
71. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1419-31.
72. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center involving clinically significant diabetic macular edema. Ophthalmology 2006;113:1706-12.
73. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-4.
74. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.
75. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8.
76. Rosenfeld PJ. Intravitreal avastin: The low cost alternative to lucentis? Am J Ophthalmol 2006;142:141-3.
77. National Eye Institute (http://www.nei.nih.gov). A phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (Avastin). [updated on 2008 May 15]; [cited on 2008 Nov 20]. Available from: http://www.nei.nih.gov/ neitrials/ viewStudyWeb.aspx? id=129.
78. PKC-DRS2 Group, Aiello LP, Davies MD, Girach A, Kles KA, Milton RC, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-30.
79. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, et al. PKC412: A protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
80. Campochiaro PA; C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004;45:922-31.
81. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study. Diabetes Care 2000;23:504-9.
82. Hernandez C, Carrasco E, Casamitjana R, Deulofeu R, Garcia-Arumi J, Simo R. Somatostatin molecular variants in the vitreous fluid: A comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care 2005;28:1941-7.
83. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991;98:766S-85S.
84. Fong DS. Changing times for the management of diabetic retinopathy. Surv Ophthalmol 2002;47:238S-45S.
85. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999;20:493-510.
86. Jeganathan VS, Wang JJ, Wong TY. Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care 2008;31:1905-12.
87. Klein BE, Klein R, Moss SE. Incidence of cataract surgery in the wisconsin epidemiologic study of diabetic retinopathy. Am J Ophthalmol 1995;119:295-300.
88. Cunliffe IA, Flanagan DW, George ND, Aggarwaal RJ, Moore AT. Extracapsular cataract surgery with lens implantation in diabetics with and without proliferative retinopathy. Br J Ophthalmol 1991;75:9-12.
89. Saxena S, Jalali S, Meredith TA, Holekamp NM, Kumar D. Management of diabetic retinopathy. Indian J Ophthalmol 2000;48:321-30.
90. Liao SB, Ku WC. Progression of diabetic retinopathy after phacoemulsification in diabetic patients: A three-year analysis. Chang Gung Med J 2003;26:829-34.
91. Hauser D, Katz H, Pokroy R, Bukelman A, Shechtman E, Pollack A. Occurrence and progression of diabetic retinopathy after phacoemulsification cataract surgery. J Cataract Refract Surg 2004;30:428-32.
92. World Health Organization (http://www.who. int). Prevention of blindness due to diabetes. Available from: http://www.who.int/blindness/ Prevention%20of%20Blindness%20from%20 Diabetes%20Mellitus-with-cover-small.pdf.
93. Stefánsson E. Prevention of diabetic blindness. Br J Ophthalmol 2006;90:2-3.
94. Mikki A. Low-vision care for rehabilitation of visually impaired due to diabetic retinopathy. Nippon Ganka Kiyo 2005;56:311-5.